Alcon launches Hydrus Microstent in India to transform glaucoma care
The Hydrus Microstent stands out as the first and only MIGS device backed by five-year clinical outcomes
The Hydrus Microstent stands out as the first and only MIGS device backed by five-year clinical outcomes
The hospitals house over 25 super-speciality centres and Centres of Excellence in Cardiology, Neurology, Oncology, Paediatrics, Orthopaedics, ENT, Obstetrics and Gynaecology, General Surgery, Internal Medicine, Critical Care, and Chronic Disease Management
The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications
Germany will be the first launch market
The first of four planned modules at the new plant is expected to come online by summer 2026
The FDA decision was based on results from the pivotal POETYK PsA-1 and POETYK PsA-2 Phase 3 trials
The document, published under the Accelerating Clinical Trials in the EU (ACT EU) initiative, sets out how trials should be conducted when health emergencies disrupt normal research operations
The company announced positive topline data from the Phase II ZUPREME-1 trial
Pivya is Alembic’s first branded pharmaceutica product in the US and is being marketed through Alembic Therapeutics LLC
Subscribe To Our Newsletter & Stay Updated